FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
February 18 2021 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and
full year 2020 financial results on Monday, March 1 after the
market close. FibroGen will also conduct a conference call on that
day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to
further detail the company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the FibroGen website at
https://fibrogen.gcs-web.com/events-and-presentations/events. It is
recommended that listeners access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software.
Dial-In InformationLive (U.S./Canada): (877)
658-9081Live (International): (602) 563-8732Confirmation number:
3055327
A replay of the webcast and investor presentation will be
available shortly after the call for a period of 30 days. To access
the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406
(international), and use passcode 3055327.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to
discovering, developing, and commercializing a pipeline of
first-in-class therapeutics. The company applies its pioneering
expertise in hypoxia-inducible factor (HIF) and connective tissue
growth factor (CTGF) biology to advance innovative medicines for
the treatment of unmet needs. The Company is currently developing
and commercializing roxadustat, an oral small molecule inhibitor of
HIF prolyl hydroxylase activity, for anemia associated with chronic
kidney disease (CKD). Roxadustat is also in clinical development
for anemia associated with myelodysplastic syndromes (MDS) and for
chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), locally advanced
unresectable pancreatic cancer (LAPC), and Duchenne muscular
dystrophy (DMD). For more information, please visit
www.fibrogen.com.
Contacts:FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor
Relations 1.415.978.1434mtung@fibrogen.com
Media:Jennifer Harrington
+1.610.574.9196Jennifer.Harrington@gcihealth.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024